<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998864</url>
  </required_header>
  <id_info>
    <org_study_id>BT008E</org_study_id>
    <nct_id>NCT04998864</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients</brief_title>
  <official_title>Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the Exablate Model 4000 Type 2.0 used&#xD;
      as a tool to disrupt the BBB in patients with high grade glioma undergoing standard of care&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the safety and feasibility of BBB disruption using the&#xD;
      Exablate Type 2.0 system in adult patients with glioblastoma (GBM) undergoing adjuvant TMZ&#xD;
      chemotherapy, which occurs following maximal safe surgical resection and completion of the&#xD;
      initial concurrent radiation-chemotherapy in accordance with the current standard of care&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>Throughout the study, approximately 12 months.</time_frame>
    <description>The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging</measure>
    <time_frame>At the time of each ExAblate MRgFUS procedure]</time_frame>
    <description>The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Glioma, Malignant</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Focused Ultrasound (FUS) BBB Disruption</arm_group_label>
    <description>The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance guided Focused ultrasound (MRgFUS)</intervention_name>
    <description>FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.</description>
    <arm_group_label>Focused Ultrasound (FUS) BBB Disruption</arm_group_label>
    <other_name>Exablate Neuro</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with glioblastoma brain tumor who will undergo surgical resection and chemotherapy&#xD;
        as standard of care with temozolomide.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is eligible for adjuvant TMZ treatment.&#xD;
&#xD;
          2. Men or women age between 18 and 80 years, inclusive.&#xD;
&#xD;
          3. Able and willing to give informed consent.&#xD;
&#xD;
          4. Grade IV glioma (GBM) confirmed Subjects&#xD;
&#xD;
          5. Karnofsky rating 70-100.&#xD;
&#xD;
          6. Able to communicate during the Exablate BBBD procedure.&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of acute intracranial hemorrhage.&#xD;
&#xD;
          2. The subject presents with severe symptoms and signs of increased intracranial pressure&#xD;
&#xD;
          3. Patients with cerebellar or brainstem tumors.&#xD;
&#xD;
          4. Patients with positive HIV status&#xD;
&#xD;
          5. Patients with brain tumors containing 1p/19q chromosomal co-deletion&#xD;
&#xD;
          6. Patient receiving bevacizumab (Avastin) therapy&#xD;
&#xD;
          7. Patients undergoing other concurrent therapies&#xD;
&#xD;
          8. Cardiac disease or unstable hemodynamics&#xD;
&#xD;
          9. Severe hypertension&#xD;
&#xD;
         10. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within&#xD;
             washout period prior to treatment&#xD;
&#xD;
         11. History of a bleeding disorder and/or coagulopathy&#xD;
&#xD;
         12. Known sensitivity to gadolinium-based contrast agents&#xD;
&#xD;
         13. Known sensitivity to ultrasound contrast agent&#xD;
&#xD;
         14. Severely impaired renal function&#xD;
&#xD;
         15. Subjects with significant liver dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Scott Bellman</last_name>
    <phone>+1 214-630-2000</phone>
    <email>Scottb@insightec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dott.ssa Giorgia Simonetti</last_name>
      <phone>+39 022394-2443</phone>
      <email>Giorgia.Simonetti@istituto-besta.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco DiMeco, MD</last_name>
      <phone>+39-348-9137180</phone>
      <email>fdimeco@istituto-besta.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco DiMeco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CINAC-Hospital HM Puerta del Sur</name>
      <address>
        <city>MÃ³stoles</city>
        <state>Madrid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma, MRgFUS, Exablate, TMZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

